U.S. markets closed

Liquid Media Group Ltd. (YVR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.21000.0000 (0.00%)
At close: 04:00PM EST
1.2000 -0.01 (-0.83%)
After hours: 06:23PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.2100
Bid1.2200 x 1400
Ask1.2700 x 800
Day's Range1.1800 - 1.2800
52 Week Range1.0700 - 7.5000
Avg. Volume686,514
Market Cap19.145M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.4060
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for YVR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Liquid Media Group Ltd.
    Analyst Report: Seagen Inc.Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    Liquid Media Finalizing Film Financing Slate, Unveils Blockchain Approach for Independent Producers and Studios

    VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Liquid Media Group Ltd. (the “Company,” “Liquid Media” or “Liquid”) (Nasdaq: YVR) is pleased to announce that it is in the final stages of an agreement to provide recoupable last-mile financing for three films through the Company’s newly formed production funding unit Liquid Media Production Funding Ltd. All three films completed Liquid’s Phase I review with high-performing scores from Liquid’s analytics partner, Slated Inc., togethe

  • GlobeNewswire

    Liquid Media Signs Definitive Agreement to Acquire iGEMStv

    VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Liquid Media Group Ltd. (“the Company,” “Liquid Media” or “Liquid”) (Nasdaq: YVR) today announced that, further to its press release dated June 9, 2021, it has executed a definitive agreement to acquire iGEMStv, Inc. (“iGEMStv”), which provides the most comprehensive content recommendation engine on the market. The closing is expected to be completed in the coming days as remaining customary closing conditions are fulfilled, and adds

  • GlobeNewswire

    Liquid Media Announced as Presenting Sponsor for Filmocracy Fest 2021

    VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Liquid Media Group Ltd. (the “Company,” “Liquid Media” or “Liquid”) (Nasdaq: YVR) is pleased to announce that it has signed on as the presenting sponsor for Filmocracy Fest 2021, which takes place December 9th to 12th, 2021 in Los Angeles and across the United States with hybrid in-person and virtual programming. The Festival is being produced by Filmocracy, the world’s premiere digital screening, distribution and experience platform